TMEFF2 and prostate carcinoma: Conversely, other reports showed that a significant proportion of prostate carcinomas exhibit TMEFF2 overexpression [46, 47] and in vivo studies using LNCaP xenografts show that TMEFF2 inhibition results in tumor growth arrest [46], favoring its role as an oncogene.